News | Radiation Therapy | October 06, 2016

New Data on Elekta's MR-Linac Presented at ASTRO 2016

Multiple presentations highlight clinical potential of MR-linac in a variety of cancers and demonstrate the need to address intra-session motion

October 6, 2016 — Elekta announced recently that its high-field magnetic resonance linear accelerator (MR-linac) was the focus of multiple presentations at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting, held Sept. 25 – 28 in Boston. Additional abstracts presented by members of Elekta’s MR-linac Consortium also highlighted the need for adaptation of radiation therapy to address moving tumors and nearby organs during treatment sessions. Naturally occurring physiological movements currently limit the ability to conform the treatment to the target and increase exposure of radiation to healthy tissues.

Elekta’s MR-linac will integrate an advanced linear accelerator and a 1.5 Tesla magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

A joint session of ASTRO and the European Society for Radiation Oncology (ESTRO) highlighted the potential for adaptive imaging in radiation therapy during a session titled “In Room Adaptive Imaging with a Focus on MRI.”  Elekta’s MR-linac was featured in two presentations during this session:

  • “Linac-based MR Device”; Christopher Schultz, M.D., FACR, professor in the Department of Radiation Oncology at Froedert and Medical College of Wisconsin. This presentation discussed strategies for integrating MR-linac into current RT protocols and provided an overview of the development plan that the Elekta MR-linac Consortium is undertaking in order to generate the clinical, physics and quality control data that will be essential for developing and realizing the full clinical potential of MR-linac technology.
  • “MRI Linac: Physics Perspective”; Bas Raaymakers, Ph.D., professor in the Department of Radiotherapy at University Medical Center Utrecht. This presentation highlighted the potential to leverage the power of MR-linac technology to move from pre-treatment planning to online plan adaptation and, ultimately, to real-time plan adaptation. Raaymakers also discussed the need for novel quality assurance procedures for MR-linac devices, patients and workflow.

Additional key findings related to the MR-linac Consortium’s development of MR-linac presented at the conference include:

  • Abdominal organ motion is complex and can occur despite motion management strategies. Abstract #3708: “Complex Abdominal Organ Motion Assessed from MRI”; Eenas Omari, Ph.D., postdoctoral fellow in the Department of Radiation Oncology at Medical College of Wisconsin;
  • Substantially improves targeting and lowers radiation dose to normal breast tissue in patients undergoing pre-operative partial breast irradiation. Abstract #3695: “Dosimetric Feasibility of Pre-operative Partial Breast Irradiation in Prone Position Using MR-linac” ; Phil Prior, Ph.D., medical physicist in the Department of Radiation Oncology at Medical College of Wisconsin;
  • Clinically acceptable treatment plans for patients with locally advanced non-small cell lung cancer can be created. Abstract #3150: “Dosimetric Implications for Radical Radiotherapy on the MR-linac (MRL) in Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)”; Hannah Bainbridge, M.D., clinical fellow lung team, The Institute of Cancer Research, Sutton, United Kingdom, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom;
  • Online adaptive replanning is feasible for prostate cancer radiation therapy. Abstract #3639: “A Hybrid Adaptive Replanning Approach for Prostate SBRT”; Ozgur Ates, Ph.D., postdoctoral fellow in the Department of Radiation Oncology at Medical College of Wisconsin; and
  • An automated quality assurance (QA) tool can quickly identify contour errors from auto-segmentation and may have utility in online adaptive replanning. Abstract #3638 “Implementation of a Machine-learning Based Automatic Contour QA Tool for Online Adaptive Radiotherapy of Prostate Cancer” ; Jing Qiao Zhang, Ph.D., postdoctoral fellow in the Department of Radiation Oncology at Medical College of Wisconsin.

 

Several additional presentations described the potential for MR-linac and adaptive therapy to enable dose painting — the precise delivery of varying doses of radiation to specific regions within a tumor in order to account for differences in cell type, location and density from one part of the tumor to another.

Elekta’s MR-linac is a work in progress and not available for sale or distribution.

For more information: www.elekta.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020
April 7, 2020 — An intern...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 A brief article from Henry Ford Health System in Detroit, published today in Radiology, reports on the first presumptive case of COVID-19–associated acute necrotizing hemorrhagic encephalopathy.

A, Image from noncontrast head CT demonstrates symmetric hypoattenuation within the bilateral medial thalami (arrows). B, Axial CT venogram demonstrates patency of the cerebral venous vasculature, including the internal cerebral veins (arrows). C, Coronal reformat of aCT angiogram demonstrates normal appearance of the basilar artery and proximal posterior cerebral arteries. Image courtesy of the Radiological Society of North America (RSNA)

News | Coronavirus (COVID-19) | March 31, 2020
March 31, 2020 — A brief article fr
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...